Ken Fisher Fisher Asset Management
AUM
$293B
1-Year Est. Return
28.33%
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
This Fund
S&P 500
1 Year Est. Return
+28.33%
AUM
$276B
AUM Growth
+$24.4B
(+9.7%)
Holding
1,094
Top Buys
| 1 | +$2.87B | |
| 2 | +$358M | |
| 3 | +$287M | |
| 4 |
Microsoft
MSFT
|
+$278M |
| 5 |
Apple
AAPL
|
+$200M |
Top Sells
| 1 | +$1.8B | |
| 2 | +$205M | |
| 3 | +$177M | |
| 4 |
Adobe
ADBE
|
+$120M |
| 5 |
Chart Industries
GTLS
|
+$95.2M |
Sector Composition
| 1 | Technology | 26.4% |
| 2 | Financials | 18.68% |
| 3 | Industrials | 9.33% |
| 4 | Healthcare | 8.68% |
| 5 | Communication Services | 6.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Coherent
COHR
$63B
| $40.4M | 0.01% |
375,496
+120,727
|
|
||
252
Veeco
VECO
$3.12B
| $40.3M | 0.01% |
1,324,590
+325,357
|
|
||
253
Granite Construction
GVA
$5.4B
| $39.7M | 0.01% |
362,505
-9,026
|
|
||
254
Biogen
BIIB
$27.1B
| $38.8M | 0.01% |
277,285
-11,852
|
|
||
255
SLB Ltd
SLB
$84.3B
| $38.7M | 0.01% |
1,125,010
-29,976
|
|
||
256
Boot Barn
BOOT
$5.13B
| $37.8M | 0.01% |
228,009
+62,515
|
|
||
257
Helmerich & Payne
HP
$3.9B
| $37.7M | 0.01% |
1,706,123
-54,418
|
|
||
258
Bio-Rad Laboratories Class A
BIO
$7.77B
| $37.4M | 0.01% |
133,465
-4,277
|
|
||
259
Abercrombie & Fitch
ANF
$3.9B
| $36.9M | 0.01% |
431,351
+40,914
|
|
||
260
Arrowhead Research
ARWR
$10.3B
| $36.3M | 0.01% |
1,053,794
+602,139
|
|
||
261
APA Corp
APA
$13.3B
| $35.2M | 0.01% |
1,449,546
+71,890
|
|
||
262
Moelis & Co
MC
$5B
| $35.1M | 0.01% |
491,470
+141,221
|
|
||
263
Agios Pharmaceuticals
AGIO
$1.48B
| $34.9M | 0.01% |
870,145
-7,395
|
|
||
264
Baker Hughes
BKR
$68.4B
| $34.9M | 0.01% |
716,879
+33,471
|
|
||
265
Nucor
NUE
$48.8B
| $34.5M | 0.01% |
254,510
+20,043
|
|
||
266
Vanguard Long-Term Treasury ETF
VGLT
$9.99B
| $34.1M | 0.01% |
599,884
-108,573
|
|
||
267
UMB Financial
UMBF
$9.31B
| $33.9M | 0.01% |
286,681
+4,420
|
|
||
268
KLA
KLAC
$254B
| $33.6M | 0.01% |
31,140
-1,673
|
|
||
269
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
$10.1B
| $33.5M | 0.01% |
1,105,148
-231,439
|
|
||
270
SPX Corp
SPXC
$11.2B
| $33M | 0.01% |
176,507
+58,326
|
|
||
|
UCB
271
United Community Banks
UCB
$3.96B
| $32.9M | 0.01% |
1,048,174
-16,755
|
|
||
272
Haemonetics
HAE
$2.79B
| $32.3M | 0.01% |
662,504
-26,638
|
|
||
273
Murphy Oil
MUR
$5.59B
| $31.7M | 0.01% |
1,117,152
-63,276
|
|
||
274
iShares MSCI Saudi Arabia ETF
KSA
$719M
| $31.7M | 0.01% |
781,350
+20,319
|
|
||
275
Crinetics Pharmaceuticals
CRNX
$4.01B
| $31.6M | 0.01% |
758,357
+21,273
|
|